Poland· PL-100423803
Tecentriq
A atezolizumab product containing atezolizumabum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Atezolizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FF05 (atezolizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Atezolizumab · ATC L01FF05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of atezolizumab costs, country by country.
Normalised to the WHO defined daily dose (89 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Atezolizumab · price per daily dose (89 mg)
USD · FX 28 Sept 2026
- CH Switzerland$377.53
The record
At a glance
URPL (Poland)- Active substance
- Atezolizumabum
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- L01FF05
- ATC class
- Atezolizumab
- Defined daily dose
- 89 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07613326025546
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
75 interactions on record for atezolizumab.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Atezolizumab · interactions on record
75 records
- 30 severe
- 45 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Atezolizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandTecentriqOrifarm Oy
- NorwayTecentriqAbacus Medicine A/S
- BelgiumTecentriq 840 mgRoche Registration
- IcelandTecentriqRoche Registration GmbH*
- SwedenTecentriq 840 mg Koncentrat till infusionsvätska, lösningRoche Registration GmbH
- IrelandTecentriq 840 mg concentrate for solution for infusionRoche Registration GmbH
- CzechiaTECENTRIQRoche Registration GmbH, Grenzach-Wyhlen
- SpainTECENTRIQ 1.200 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tecentriq
- Liechtenstein · Tecentriq
- Norway · Tecentriq
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0482e503-40a8-457e-9633-57282f60983d GET /v1/drugs/0482e503-40a8-457e-9633-57282f60983d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "840 mg",
"packaging": "07613326025546 ¦ Rpz ¦ EU/1/17/1220/002 ¦ 133680\n1 fiol. 14 ml",
"substance": "Atezolizumabum 60 mg/ml",
"common_name": "Atezolizumabum",
"pl_product_id": "100423803",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about atezolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.